|Titre :||Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans (2003)|
|Auteurs :||R. A. GUSTAFSON ; B. LEVINE ; P. R. STOUT ; K. L. KLETTE ; M. P. GEORGE ; E. T. MOOLCHAN ; M. A. HUESTIS|
|Type de document :||Article : Périodique|
|Dans :||Clinical Chemistry (Vol.49, n°7, July 2003)|
|Article en page(s) :||1114-1124|
|Note générale :||
Clinical Chemistry, 2003, 49, (7), 1114-1124
Editorial p.1037-1038 : "Practical challenges to positive drug tests for marijuana", ElSohly M.A.
|Discipline :||PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)|
Thésaurus TOXIBASETETRAHYDROCANNABINOL ; DEPISTAGE ; URINE ; CANNABIS ; METHODE ; TEST
|Résumé :||BACKGROUND: Urinary cannabinoid excretion and immunoassay performance were evaluated by semiquantitative immunoassay and gas chromatography-mass spectrometry (GC/MS) analysis of metabolite concentrations in 4381 urine specimens collected before, during, and after controlled oral administration of tetrahydrocannabinol (THC). METHODS: Seven individuals received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day in this double-blind, placebo-controlled, randomized, clinical study conducted on a closed research ward. THC doses (hemp oils with various THC concentrations and the therapeutic drug Marinol®) were administered three times daily for 5 days. All urine voids were collected over the 10-week study and later tested by Emit II®, DRI®, and CEDIA® immunoassays and by GC/MS. Detection rates, detection times, and sensitivities, specificities, and efficiencies of the immunoassays were determined. RESULTS: At the federally mandated immunoassay cutoff (50 g/L), mean detection rates were|
|Domaine :||Drogues illicites / Illicit drugs|
Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224
Etats-Unis. United States.
|Centre Emetteur :||13 OFDT|